290 related articles for article (PubMed ID: 11518075)
41. Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin.
Tadros MG; Mohamed MR; Youssef AM; Sabry GM; Sabry NA; Khalifa AE
Behav Brain Res; 2009 May; 199(2):334-9. PubMed ID: 19136030
[TBL] [Abstract][Full Text] [Related]
42. Effects of St John's wort and its active constituents, hypericin and hyperforin, on isolated rat urinary bladder.
Valeri A; Capasso R; Valoti M; Pessina F
J Pharm Pharmacol; 2012 Dec; 64(12):1770-6. PubMed ID: 23146040
[TBL] [Abstract][Full Text] [Related]
43. In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models.
Gobbi M; Moia M; Funicello M; Riva A; Morazzoni P; Mennini T
Planta Med; 2004 Jul; 70(7):680-2. PubMed ID: 15303261
[TBL] [Abstract][Full Text] [Related]
44. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.
Müller WE; Singer A; Wonnemann M; Hafner U; Rolli M; Schäfer C
Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():16-21. PubMed ID: 9684943
[TBL] [Abstract][Full Text] [Related]
45. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(1):15-22. PubMed ID: 15727160
[TBL] [Abstract][Full Text] [Related]
46. Fast high-performance liquid chromatographic analysis of naphthodianthrones and phloroglucinols from Hypericum perforatum extracts.
Tolonen A; Hohtola A; Jalonen J
Phytochem Anal; 2003; 14(5):306-9. PubMed ID: 14516003
[TBL] [Abstract][Full Text] [Related]
47. St John's wort, a herbal antidepressant, activates the steroid X receptor.
Wentworth JM; Agostini M; Love J; Schwabe JW; Chatterjee VK
J Endocrinol; 2000 Sep; 166(3):R11-6. PubMed ID: 10974665
[TBL] [Abstract][Full Text] [Related]
48. The Biochemical and Genetic Basis for the Biosynthesis of Bioactive Compounds in
Rizzo P; Altschmied L; Ravindran BM; Rutten T; D'Auria JC
Genes (Basel); 2020 Oct; 11(10):. PubMed ID: 33081197
[No Abstract] [Full Text] [Related]
49. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract.
Cott JM
Pharmacopsychiatry; 1997 Sep; 30 Suppl 2():108-12. PubMed ID: 9342770
[TBL] [Abstract][Full Text] [Related]
50. Short term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse.
Bray BJ; Brennan NJ; Perry NB; Menkes DB; Rosengren RJ
Life Sci; 2002 Feb; 70(11):1325-35. PubMed ID: 11883710
[TBL] [Abstract][Full Text] [Related]
51. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.
Muruganandam AV; Bhattacharya SK; Ghosal S
Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529
[TBL] [Abstract][Full Text] [Related]
52. Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L.
Sosa S; Pace R; Bornancin A; Morazzoni P; Riva A; Tubaro A; Della Loggia R
J Pharm Pharmacol; 2007 May; 59(5):703-9. PubMed ID: 17524236
[TBL] [Abstract][Full Text] [Related]
53. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system.
Simmen U; Burkard W; Berger K; Schaffner W; Lundstrom K
J Recept Signal Transduct Res; 1999; 19(1-4):59-74. PubMed ID: 10071750
[TBL] [Abstract][Full Text] [Related]
54. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
Wang EJ; Barecki-Roach M; Johnson WW
J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009
[TBL] [Abstract][Full Text] [Related]
55. Antagonist effect of pseudohypericin at CRF1 receptors.
Simmen U; Bobirnac I; Ullmer C; Lübbert H; Berger Büter K; Schaffner W; Schoeffter P
Eur J Pharmacol; 2003 Jan; 458(3):251-6. PubMed ID: 12504780
[TBL] [Abstract][Full Text] [Related]
56. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
[TBL] [Abstract][Full Text] [Related]
57. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment.
Butterweck V; Korte B; Winterhoff H
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S2-7. PubMed ID: 11518068
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of vesicular uptake of monoamines by hyperforin.
Roz N; Mazur Y; Hirshfeld A; Rehavi M
Life Sci; 2002 Sep; 71(19):2227-37. PubMed ID: 12215370
[TBL] [Abstract][Full Text] [Related]
60. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders.
Sarris J; Kavanagh DJ
J Altern Complement Med; 2009 Aug; 15(8):827-36. PubMed ID: 19614563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
